SYNCOMF Stock Overview
Manufactures, markets, and sells pharmaceutical formulation products in India.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Syncom Formulations (India) Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹21.26 |
| 52 Week High | ₹27.90 |
| 52 Week Low | ₹9.05 |
| Beta | 1.4 |
| 11 Month Change | 8.69% |
| 3 Month Change | 35.67% |
| 1 Year Change | 133.63% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 162.47% |
Recent News & Updates
Recent updates
Syncom Formulations (India) Limited's (NSE:SYNCOMF) 27% Price Boost Is Out Of Tune With Earnings
Aug 30
Syncom Formulations (India) Limited's (NSE:SYNCOMF) 27% Price Boost Is Out Of Tune With Earnings
Jul 16Some Syncom Formulations (India) Limited (NSE:SYNCOMF) Shareholders Look For Exit As Shares Take 28% Pounding
Mar 21Syncom Formulations (India) Limited's (NSE:SYNCOMF) 27% Price Boost Is Out Of Tune With Earnings
Dec 29Syncom Formulations (India) Limited's (NSE:SYNCOMF) Shares Climb 26% But Its Business Is Yet to Catch Up
Dec 27Shareholder Returns
| SYNCOMF | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 7.2% | 1.5% | 0.2% |
| 1Y | 133.6% | 54.6% | 35.3% |
Return vs Industry: SYNCOMF exceeded the Indian Pharmaceuticals industry which returned 54.6% over the past year.
Return vs Market: SYNCOMF exceeded the Indian Market which returned 35.3% over the past year.
Price Volatility
| SYNCOMF volatility | |
|---|---|
| SYNCOMF Average Weekly Movement | 10.3% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: SYNCOMF's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: SYNCOMF's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 998 | Vijay Bankda | www.syncomformulations.com |
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It operates through Manufacturing and Dealing in Pharmaceutical Drug & Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, gynae, opthal, ortho, and pediatrics formulations.
Syncom Formulations (India) Limited Fundamentals Summary
| SYNCOMF fundamental statistics | |
|---|---|
| Market cap | ₹20.01b |
| Earnings (TTM) | ₹285.50m |
| Revenue (TTM) | ₹2.91b |
70.1x
P/E Ratio6.9x
P/S RatioIs SYNCOMF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYNCOMF income statement (TTM) | |
|---|---|
| Revenue | ₹2.91b |
| Cost of Revenue | ₹1.76b |
| Gross Profit | ₹1.15b |
| Other Expenses | ₹864.12m |
| Earnings | ₹285.50m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 11, 2024
| Earnings per share (EPS) | 0.30 |
| Gross Margin | 39.53% |
| Net Profit Margin | 9.82% |
| Debt/Equity Ratio | 25.2% |
How did SYNCOMF perform over the long term?
See historical performance and comparison